Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1028 • ACR Convergence 2022
How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA?
Conor Coyle¹, Caroline Whately-Smith², Melanie Brooke³, Uta Kiltz⁴, Ennio Lubrano⁵, Ruben Queiro⁶, David Trigos⁷, Jan Brandt-Juergens⁸, Salvatore D'Angelo⁹, Andrea Delle Sedie¹⁰, Emmanuelle Dernis¹¹, Philip Helliwell¹², Pauline Ho¹³, Axel Hueber¹⁴, BEATRIZ E. JOVEN¹⁵, Michaela Koehm¹⁶, Carlos Montilla¹⁷, Jon Packham¹⁸, JOSE PINTO TASENDE¹⁹, Felipe Julio Ramirez Garcia²⁰, Adeline Ruyssen-Witrand²¹, Rossana Scrivo²², sarah twigg²³, Martin Welcker²⁴, Theo Wirth²⁵, Laure Gossec²⁶ and Laura Coates²⁷, ¹Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ²Whately-Smith Ltd, Kings Langley, United Kingdom, ³Bath Institute for Rheumatic Disease, Bath, United Kingdom, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, ⁶Faculty of Medicine, Rheumatology Service & the Principality of Asturias Institute for Health Research (ISPA), Universidad de Oviedo, Oveido, Spain, ⁷Patient partner, Oveido, Spain, ⁸Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁹Rheumatology Department of Lucania - San Carlo Hospital of Potenza, Potenza, Italy, ¹⁰University of Pisa, Pisa, Pisa, Italy, ¹¹LE MANS general hospital, LE MANS, France, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ¹³The Kellgren Centre for Rheumatology, Manchester, United Kingdom, ¹⁴Paracelsus University Nürnberg, Erlangen, Germany, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Rheumatology Goethe-University Frankfurt, Frankfurt Am Main, Germany, ¹⁷Complejo asistencial Universitario de Salamanca, Salamanca, Spain, ¹⁸University of Nottingham, Stafford, United Kingdom, ¹⁹SERGAS, A Coruña, Spain, ²⁰Hospital Clínic, Barcelona, Spain, ²¹CHU de Toulouse, Toulouse, France, ²²Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy, Roma, Rome, Italy, ²³Bradford Teaching hospitals NHS foundation trust, Bradford, United Kingdom, ²⁴GBR, Planegg, Germany, ²⁵Aix Marseille University, Marseille, France, ²⁶Sorbonne Université, Paris, France, ²⁷Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous, multi-dimensional disease. Little is known about factors underpinning treatment intensification in routine practice. Treatment pathways are not well…
Abstract Number: 1161 • ACR Convergence 2022
IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis
Marie-Christin Hoffmann¹, Natalie Fadle¹, Evi Regitz¹, Klaus-Dieter Preuss¹, Marina Zaks², Elisabeth Stöger³, Vincent Zimmer⁴, Philipp Klemm⁵, Gunter Assmann⁶, Bernhard Thurner⁷, Claudia Pföhler⁸, Joerg Thomas Bittenbring¹, Christoph Kessel⁹ and Lorenz Thurner¹, ¹José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany, ²Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany, ³Evangelische Kliniken Essen-Mitte gGmbH, Evangelische Huyssens-Stiftung Essen-Huttrop, Essen, Germany, Essen, Germany, ⁴Department of Medicine, Knappschaftsklinikum Saar, Püttlingen, Germany, Department of Medicine II, Saarland University Medical School, Homburg/Saar, Germany, ⁵Campus Kerckhoff of Justus Liebig University Giessen, Bad Nauheim, Germany, ⁶Klinik für Rheumatologie und klinische Immunologie, Mühlenkreiskliniken, Johannes Wesling Klinikum Minden, Minden, Germany, Minden, Germany, ⁷Department of Pediatrics, Klinikum Kempten, Kempten, Germany, ⁸Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany, ⁹Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany, Münster, Germany
Background/Purpose: Psoriasis arthritis is known as a subtype of seronegative spondylarthritis. However, autoantibodies against the receptor antagonist at tumor necrosis factor receptor 1 and 2…
Abstract Number: 1487 • ACR Convergence 2022
Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23
James Krueger¹, Kilian Eyerich², Dennis McGonagle³, Carrie Greving⁴, Kacey Sachen⁴, Deepa Hammaker⁴, Phuc Bao⁴, Eilyn Lacy⁴, M. Merle Elloso⁵, Yevgeniya Orlovsky⁵, Iain B McInnes⁶ and Anne Fourie⁷, ¹The Rockefeller University, New York, NY, ²Technical University, Munich, Germany / Karolinska Institute, Stockholm, Sweden, ³University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁴Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁷Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA
Background/Purpose: Clinically relevant differences between therapeutic antibodies against the same target may relate to their unique molecular attributes. Differences in therapeutic profiles across the domains…
Abstract Number: 1597 • ACR Convergence 2022
Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial
Frank Behrens¹, Peter Taylor², Philip J Mease³, Paul Peloso⁴, Dieter Wetzel⁵, Nicolai Brun⁵, Brian Wiens⁶, Jan Brandt-Juergens⁷, Edit Drescher⁸, Eva Dokoupilova⁹, Anna Rowińska-Osuch¹⁰, Nadia Abdel- Kader Martin¹¹ and Kurt de Vlam¹², ¹Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ²University of Oxford, Oxford, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴ACELYRIN, Naples, FL, ⁵Affibody AB, Solna, Sweden, ⁶ACELYRIN, Inc., Los Angeles, CA, ⁷Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁸Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, ⁹Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, ¹⁰ETG Network - Rheumatology, Warsaw, Poland, ¹¹Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, ¹²University Hospitals Leuven, Leuven, Belgium
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, inflammatory disease with multiple clinical manifestations (arthritis, spondylitis, enthesitis, dactylitis, skin, nails). IL-17 inhibitors have shown efficacy across…
Abstract Number: 2108 • ACR Convergence 2022
Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA
Stefan Siebert¹, Georg Schett², Siba P. Raychaudhuri³, Monica Guma⁴, Warner Chen⁵, Sheng Gao⁵, Soumya Chakravarty⁶, May Shawi⁷ and Proton Rahman⁸, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Universitätsklinikum Erlangen, Erlangen, Germany, ³Rheumatology, Allergy, and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Memorial University, St. John's, NL, Canada
Background/Purpose: The IL-23p19 inhibitor guselkumab has shown robust efficacy vs placebo (PBO) in the phase 3 DISCOVER-1 and DISCOVER-2 studies of adults with active PsA,1,2…
Abstract Number: 2124 • ACR Convergence 2022
Immunological Differences Between PsA Patients Who Are Tumor Necrosis Factor Inhibitor-Naïve and Who Have Inadequate Response to Tumor Necrosis Factor Inhibitors
Stefan Siebert¹, Laura Coates², Georg Schett³, Siba P. Raychaudhuri⁴, Warner Chen⁵, Sheng Gao⁵, Soumya Chakravarty⁶, May Shawi⁷, Frederic Lavie⁸, Elke Theander⁹, Marlies Neuhold¹⁰, Alexa Kollmeier¹¹, Xie L Xu¹², Proton Rahman¹³, Philip J Mease¹⁴ and Atul Deodhar¹⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Rheumatology, Allergy, and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, Paris, France, ⁹Janssen Cilag, Lund, Sweden, ¹⁰Janssen, Zug, Switzerland, ¹¹Janssen-Cilag, Research & Development, LLC, San Diego, CA, ¹²Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, ¹³Memorial University, St. John's, NL, Canada, ¹⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ¹⁵Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: A better understanding of the immunological differences between psoriatic arthritis (PsA) patients (pts) who are tumor necrosis factor inhibitor (TNFi)-naïve and who have inadequate…
Abstract Number: 2141 • ACR Convergence 2022
How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study
Maria-Antonietta D'Agostino¹, Philip G Conaghan², Corine Gaillez³, Esperanza Naredo⁴, Peter mandl⁵, Philippe Carron⁶, Ladislav Šenolt⁷, Javier Eduardo Rosa⁸, Alejandra Lopez Rdz⁹, Punit Goyanka¹⁰, Braja Gopal Sahoo¹⁰, Weibin Bao¹¹, Georg Schett¹² and Maarten Boers¹³, ¹Catholic University of Sacred Heart, Roma, Italy, ²University of Leeds, Leeds, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, ⁵Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Dermatológico Country, PSOAPS Psoriasis Clinical and Research Centre, Guadalajara, Mexico, ¹⁰Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹²Universitätsklinikum Erlangen, Erlangen, Germany, ¹³Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands
Background/Purpose: Power Doppler ultrasound (PDUS) allows the visualization of morphological and inflammatory changes of the synovium. The ULTIMATE study (NCT02662985) was the first large, randomized,…
Abstract Number: 2256 • ACR Convergence 2022
Increased Brain Functional Connectivity to the Insula Is Associated with Nociplastic Pain in Psoriatic Arthritis
Flavia Sunzini¹, Kristian Stefanov¹, Salim Al-Wasity¹, Steven E Harte², Richard E Harris², Daniel J Clauw², Stefan Siebert³, Carl Goodyear¹, Gordon Waiter⁴ and Neil Basu¹, ¹University of Glasgow, Glasgow, Scotland, United Kingdom, ²University of Michigan, Ann Arbor, MI, ³Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴University of Aberdeen, Aberdeen, Scotland, United Kingdom
Background/Purpose: Pain is a hallmark feature of psoriatic arthritis (PsA); however, its apparent multi-factorial nature makes it difficult for rheumatologists to assess and manage. Clinically,…
Abstract Number: 0088 • ACR Convergence 2022
Challenges in the Management of Psoriatic Arthritis in Latin America: A Systematic Review
Andre Ribeiro¹, Larissa Dullius², Andre Azeredo², Laura Coates³, Odirlei Monticielo², Charles Kohem², Penelope Palominos² and Natalia Sartori¹, ¹Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, ²Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: In 2020, the International League of Associations for Rheumatology (ILAR) recommendations for management of psoriatic arthritis (PsA) were published. It aimed to adapt GRAPPA…
Abstract Number: 0391 • ACR Convergence 2022
Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data
William Tillett¹, Alexander Egeberg², Enikö Sonkoly³, Patricia Gorecki⁴, Anna Tjärnlund⁵, Jozefien Buyze⁶, Sven Wegner⁷ and Dennis McGonagle⁸, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ³Dermatology and Venereology Division, Karolinska Institutet; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Janssen-Cilag Ltd, High Wycombe, United Kingdom, ⁵Janssen-Cilag AB, Solna, Sweden, ⁶Janssen Pharmaceutica NV, Beerse, Belgium, ⁷Janssen-Cilag GmbH, Neuss, Germany, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Nail psoriasis can be difficult to treat, affects ~50% of patients with psoriasis and can involve the nail matrix (pitting, leukonychia) and/or nail bed…
Abstract Number: 0807 • ACR Convergence 2022
High Throughput Analyses for the Study of Synovial Tissue Biopsy from Inflammatory Arthritis Patients
Viviana Marzaioli¹, Achilleas Floudas², Aine Gorman³, Carl Orr⁴, Douglas Veale⁵ and Ursula Fearon⁶, ¹Trinity College Dublin and University College Dublin, Dublin, Ireland, ²Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ³St Vincent's University Hospital, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin, Ireland, ⁵St. Vincent's University Hospital, Blackrock, Dublin, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: Inflammatory arthritis (IA) is a chronic systemic autoimmune disease of unknown aetiology, which affects the joints. While studies of immune cell populations in peripheral…
Abstract Number: 1031 • ACR Convergence 2022
Foot Involvement in Psoriatic Arthritis- a Retrospective Study
Sofia Ferreira Azevedo¹, Carolina Mazeda², Susana P. Silva³, Claudia P. Oliveira¹ and Anabela Barcelos³, ¹Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ²Centro Hospitalar Baixo Vouga, Ovar, Portugal, ³Centro Hospitalar Baixo Vouga, Aveiro, Portugal
Background/Purpose: Foot involvement is well recognized in many inflammatory rheumatic diseases, namely in Spondylarthritis (SpA), where its early recognition is of utmost importance. Psoriatic arthritis…
Abstract Number: 1188 • ACR Convergence 2022
Diabetes Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting
Kate Orroth¹, Cristi Cavanaugh², Xi Qian², Pam Kumparatana², Yuri Klyachkin³, Stephen Colgan⁴ and Myriam Cordey⁴, ¹Amgen, Manhattan Beach, CA, ²OM1, Inc., Boston, MA, ³Amgen, Lexington, KY, ⁴Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Patients with PsO and PsA have a higher prevalence of cardiometabolic comorbidities like diabetes compared to the general population. Clinical data have shown apremilast…
Abstract Number: 1488 • ACR Convergence 2022
Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study
David Singer¹, Philippe Thompson-Leduc², Siyu Ma³, Deepshekhar Gupta⁴, Wendy Cheng⁵, Selvam Sendhil⁶, Manasvi Sundar⁶, Ella Hagopian⁵, Mei Sheng Duh⁷ and Sara Poston¹, ¹GSK, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³GSK/Tufts Medical Center, Boston, MA, ⁴Analysis Group, Inc., Menlo Park, CA, ⁵Analysis Group, Inc., Boston, MA, ⁶Analysis Group, Inc., Los Angeles, CA, ⁷Analysis Group Inc, Boston, MA
Background/Purpose: Patients with psoriatic arthritis (PsA) may be at increased risk of herpes zoster (HZ). HZ can involve a painful dermatomal rash and lead to…
Abstract Number: 1598 • ACR Convergence 2022
Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Philip J Mease¹, Atul Deodhar², Désirée van der Heijde³, Frank Behrens⁴, Alan Kivitz⁵, Jeffrey Neal⁶, Marleen Nys⁷, Tom Lehman⁷, Nikolay Delev⁷, Shimon Korish⁷, Miroslawa Nowak⁷ and Subhashis Banerjee⁷, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Oregon Health & Science University, Portland, OR, USA, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴CIRI/Rheumatology and Fraunhofer Institute, Translational Medicine and Pharmacology ITMP, Goethe University, Frankfurt, Germany, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Arthritis Center of Lexington, University of Kentucky School of Medicine, Lexington, KY, ⁷Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib (DEUC) is a novel, oral, selective, allosteric inhibitor of tyrosine kinase 2 (TYK2) that acts by binding to the unique TYK2 regulatory domain,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].